Loading clinical trials...

Bryostatin-1 in Treating Patients With Recurrent Non-Hodgkin's Lymphoma | Clinical Trials | Clareo Health

COMPLETEDPHASE2

Bryostatin-1 in Treating Patients With Recurrent Non-Hodgkin's Lymphoma

PHASE II EVALUATION OF BRYOSTATIN-1 (NSC 339555) IN NON-HODGKIN'S LYMPHOMA

NCT00002725•National Cancer Institute (NCI)

Summary

Phase II trial to study the effectiveness of bryostatin-1 in treating patients with recurrent non-Hodgkin's lymphoma. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.

Detailed Description

OBJECTIVES: I. Determine the response to bryostatin 1 (BRYO) administered weekly for 3 weeks in patients with relapsed non-Hodgkin's lymphoma. II. Assess the toxic effects of this treatment. III. Establish the correlation between PKC isoenzyme activity and BRYO function in lymphoma cells and normal lymphocytes. IV. Determine the pharmacokinetic profile of BRYO and its relationship to pharmacodynamics. OUTLINE: Single-Agent Chemotherapy/Differentiation Therapy. Bryostatin 1, BRYO, NSC-339555.

Eligibility

Age

All ages

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•DISEASE CHARACTERISTICS:
•Histologically confirmed non-Hodgkin's lymphoma
•Working formulation low-, intermediate-, and high-grade histologies eligible
•Mantle cell and marginal zone lymphoma eligible
•Relapse after at least 1 doxorubicin-containing regimen required
•No more than 2 prior chemotherapy regimens
•One prior biologic therapy in addition to the 2 prior chemotherapy regimens allowed
•No prior bone marrow transplantation
•Ineligible for treatment on higher priority protocols
•Patients eligible for bone marrow transplantation may be treated to reduce tumor bulk
+17 more criteria

Locations (1)

University of Texas - MD Anderson Cancer Center

Houston, Texas, United States

Key Dates

Start Date

August 1, 1996

Primary Completion Date

April 1, 2000

Last Updated

February 5, 2013

Enrollment

ACTUAL participants

Conditions

Lymphoma

Interventions

bryostatin 1

DRUG

chemotherapy

DRUG

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

NCT06337318

Classic Follicular LymphomaFollicular Lymphoma With Unusual Cytological Features

View study

RECRUITINGPHASE1

Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma

NCT07388563

Lymphoma, T Cell, PeripheralT-cell Lymphoma+4 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 5, 2013Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Bryostatin-1 in Treating Patients With Recurrent Non-Hodgkin's Lymphoma

Inclusion Criteria

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma

Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients

U69-CART-Cells For R/R T-ALL